Outcomes of transfemoral transcatheter aortic valve implantation (TAVI) and predictors of thirty-day major adverse cardiovascular events (MACE) and one-year mortality

Eftychiou, Christos; Eteocleous, Nicolaos; Zittis, Ioannis; Simamonian, Krikor; Ioannou, Antonis; Loukaidou, Pantelitsa; Ntaka, Aliki; Hadjigregoriou, Aris; Vasiliades, Vasilis; Adamou, Maria; Constantinou, Eleni; Avraamides, Panayiotis

doi:10.1016/j.hjc.2020.09.011

Cited by 13 publications

(5 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Low baseline expression of miR-223 was associated with MACCE in univariate analysis (HR: 2.71, 95% CI: 1.04–7.01; p = 0.041). However, after including the covariates (age, gender [male], New York Heart Association [NYHA] class and diabetes ([ 4 – 6 ]) into the multivariate Cox regression model, miR-223 did not reach statistical significance [HR: 2.56, 95% CI: 0.79–8.33; p = 0.118; Table 3 ).…”

Section: Resultsmentioning

confidence: 99%

“…Although the outcomes after TAVI are improving, with the 5-year survival rate at 48% [2], 29% of patients annually experience major adverse cardiac and cerebrovascular events (MACCE) after TAVI [3]. Factors associated with MACCE include increased body mass index (BMI), reduced left ventricular ejection fraction (LVEF), carotid or peripheral artery disease, high aortic valve calcium score and SYNTAX score [4][5][6]. Nevertheless, none of these factors predict post-TAVI MACCE with clinically relevant sensitivity and specificity in an individual patient.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of miR-223 to predict outcomes after transcatheter aortic valve implantation

et al. 2024

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Expression of miR-223 to predict outcomes after transcatheter aortic valve implantation

et al. 2024

View full text Add to dashboard Cite

show abstract

“…Age, COPD, EF < 30%, permanent preoperative AF, End Stage Kidney Disease on dialysis, blood transfusion, stroke/TIA and in-hospital stay emerged as long-term mortality independent predictors. All of these factors are well known in the literature for their predictiveness [24,25,[29][30][31][32][33][34][35][36] (Table 5).…”

Section: Discussionmentioning

confidence: 99%

Coronary Revascularization after Transcatheter and Surgical Aortic Valve Replacement

Gabbieri,

Giorgi,

Mascheroni

et al. 2023

JCM

View full text Add to dashboard Cite

Introduction: Due to the selective criteria and short-term follow-up of previous transcatheter aortic valve implantation (TAVI) trials, the coronary revascularization incidence after TAVI has been difficult to determine. This study investigated the epidemiology of coronary revascularization after surgical aortic valve replacement (SAVR) and TAVI in patients with severe aortic valve stenosis (AS), with and without coronary artery disease (CAD), in a mid-term follow-up, single-center, real-world setting. Methods: Between 2010 to 2020, 1486 patients with AS underwent SAVR or TAVI with balloon-expandable Edwards® transcatheter heart valves (THVs). Using hospital discharge records, we could estimate for each patient resident in Emilia Romagna the rate of ischemic events treated with percutaneous coronary intervention (PCI). A subgroup without CAD was also analyzed. Results: The 5-year overall survival was 78.2%. Freedom from PCI after AVR and TAVI at 5 years was 96.9% and 96.9%, respectively, with previous PCI as a predictor (HR 4.86, 95% CI 2.57–9.21 p < 0.001). The freedom from PCI curves were not significantly different. Conclusions: Notwithstanding the aged population, the revascularization incidence was only 2.4%, requiring further evaluation even in younger patients with longer follow-up. Despite the profile frame raise due to the evolution of Edwards® balloon-expandable THVs, PCI or coronarography feasibility were not compromised in our population.

show abstract

“…З усіх відомих на сьогодні доступів -стегновий, підключичний, апікальний, аортальний, сонний і кавальний -перевагу віддають стегновому артеріальному доступу. Завдяки стоншенню системи доставки, використанню розширювальних інтродюсерів та методики без інтродюсера успішність такого методу становить близько 90 %, а частота серйозних ускладнень знизилася до майже 2 % [15]. Для тих пацієнтів, у яких неможливо застосувати такий підхід, найбільш безпечним вважається підключичний [21].…”

Section: судинний доступunclassified

TAVI: past, present and future. On the 20th anniversary of the world’s first endovascular aortic valve implant

Stan¹,

Khokhlov²,

Zelenchuk³

et al. 2020

CSIC

View full text Add to dashboard Cite

2022 is a special year for the development of world cardiology: two important events are celebrated, namely the 40th anniversary of the first percutaneous angioplasty performed by Andreas Gruentzig (Switzerland) in September 1977 and the 20th anniversary of the first successful transcatheter aortic valve implantation (TAVI) in humans. Undoubtedly, these two techniques changed the development of the cardiovascular field of medicine for many decades. The spread of aortic stenosis, as the most common acquired heart disease, allows us to understand the importance of the latest methods of its correction. The growing prevalence of use and changes in indications for this operation require the collaboration of specialists in various specialties: cardiologists, cardiac surgeons, anesthesiologists, resuscitators, perfusiologists, rheumatologists, electrophysiologists and others. To implement the method in medical institutions, separate teams of doctors «Heart Team» are created that not only participate in the selection of patients, but also participate in the implementation of TAVI. Gaining experience, creating an optimal design and reducing the diameter of the delivery catheters has led to a reduction in the incidence of complications and the possibility of use in lower risk groups.

show abstract

Outcomes of transfemoral transcatheter aortic valve implantation (TAVI) and predictors of thirty-day major adverse cardiovascular events (MACE) and one-year mortality

Cited by 13 publications

References 51 publications

Expression of miR-223 to predict outcomes after transcatheter aortic valve implantation

Expression of miR-223 to predict outcomes after transcatheter aortic valve implantation

Coronary Revascularization after Transcatheter and Surgical Aortic Valve Replacement

TAVI: past, present and future. On the 20th anniversary of the world’s first endovascular aortic valve implant

Contact Info

Product

Resources

About